Gregg E. Franklin, MD, PhD, FACRO
Dr. Franklin is the Clinical Director of Radiation Oncology at the New Mexico Cancer Center, a multi-specialty group practice. He has been working there since 2005 after completing his residency at the Mallinkrodt Radiation Institute at Washington University/Barnes Jewish Hospital in St. Louis, MO. Prior to his MD degree, Dr. Franklin earned a PhD in condensed matter physics at the University of Illinois at Urbana-Champaign. He was also a postdoctoral fellow at Harvard University and a scientist with Sandia National Laboratory in Albuquerque, NM.
Dr. Franklin’s Statement
I have been a member of ACRO since receiving a resident travel award to attend the 2004 annual meeting. I was elected to the ACRO Board of Chancellors in 2010 after serving as Scientific Program Chair and organizing the annual meetings for two years. I have also been actively involved over the past ten years with other oncology organizations, including ASTRO and ASCO. I have participated on a number of committees, some as the chair and vice-chair, focused on trying to better the clinical practice of radiation oncology, and I have gained an appreciation of the issues and challenges not only facing radiation oncology but oncology practice generally. These issues are complex and will require all oncology organizations to work together to effect change. I recognize the importance of diversity and of differing points of view, such as between academic and community radiation oncologists and within hospitals and freestanding centers (my practice is involved with both). While technology and the need for integrating new innovative therapeutic strategies continues to accelerate, we are beset by significant economic challenges. I believe ACRO must be at the forefront of these challenges and help our members understand and utilize these changes so their practices will continue to thrive and deliver high quality care for their patients. To address these challenges, ACRO must remain a pre-eminent voice within radiation oncology to help shape the future of clinical care, education, quality, accreditation, economics and advocacy. If elected, I promise that I will always listen to, and respect, the varying opinions and positions of all members of ACRO and to work to keep radiation oncology a viable and thriving specialty within medicine.
Sheila Rege, MD, FACRO
Dr. Rege (pronounced REGGAE like the music) attended college at University of California, Berkeley at age 19. Her medical school and residency (nuclear medicine and radiation oncology) were at UCLA. Dr. Rege did extra brachytherapy training with Dr. Syed, Dr. Demanes and Dr. Grimm. She is clinical faculty at Pacific Northwest University of Health Sciences and practices at Northwest Cancer Clinic in Kennewick, Washington, with experience in Stereotactic and External Beam Radiation as well as Brachytherapy. Dr. Rege has served as President of the Benton Franklin Medical Society and is on the Washington State Medical Association Board. She serves as Vice Chair of the WA state AMA Delegation. Dr. Rege currently sits on the ACRO Board; and is Chair of the ACRO Government Relations and Economics Committee. She is the specialty advisor for radiation oncology for ACRO to AMA committees dealing with payment reform.
Dr. Rege’s Statement
The role of vice president of ACRO is an honor, and of profound importance for our specialty. I feel my unique qualifications make me well suited to serve as Vice President of ACRO at this crucial time. Please reach me through SheilaRegeMD.com anytime. I am a past member of ASTRO committees (Work Force & Government Relations/Congressional Relations Subcommittee & Code Development/Utilization). I am a strong voice for ACRO for equitable reimbursement to the specialty. Personally I have led my group through a hospital contract termination after an 18 year relationship. This resulted in us successfully opening a radiation oncology clinic in 2012. In this capacity I have had to implement budgets, negotiate contracts and market our new clinic. We did our own billing, received ACRO accreditation, started RTOG protocol research as well as a 501-3C nonprofit, Northwest Cancer Foundation. In 2015 we began a joint venture with 21C Oncology. I respectfully ask for your vote so I can bring these experiences to serve as VP for ACRO.